Patents by Inventor Kentaro YASHIRO
Kentaro YASHIRO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11851428Abstract: Disclosed is a compound of formula (I): wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and methods of using the compounds, compositions and kits for treatment of disorders associated with TREK-1, TREK-2 or both TREK-1 and TREK-2 dysfunction in a mammal.Type: GrantFiled: May 24, 2021Date of Patent: December 26, 2023Assignees: ONO PHARMACEUTICAL CO., LTD., VANDERBILT UNIVERSITYInventors: Craig W. Lindsley, Joshua M. Wieting, Kevin M. Mcgowan, Jerod S. Denton, Kentaro Yashiro, Haruto Kurata, Yoko Sekioka, Takahiro Mori, Yuzo Iwaki
-
Publication number: 20210347773Abstract: Disclosed is a compound of formula (I): wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and methods of using the compounds, compositions and kits for treatment of disorders associated with TREK-1, TREK-2 or both TREK-1 and TREK-2 dysfunction in a mammal.Type: ApplicationFiled: May 24, 2021Publication date: November 11, 2021Applicants: ONO PHARMACEUTICAL CO., LTD., VANDERBILT UNIVERSITYInventors: Craig W. LINDSLEY, Joshua M. WIETING, Kevin M. MCGOWAN, Jerod S. DENTON, Kentaro YASHIRO, Haruto KURATA, Yoko SEKIOKA, Takahiro MORI, Yuzo IWAKI
-
Patent number: 11046683Abstract: Disclosed is a compound of formula (I): wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and methods of using the compounds, compositions and kits for treatment of disorders associated with TREK-1, TREK-2 or both TREK-1 and TREK-2 dysfunction in a mammal.Type: GrantFiled: December 14, 2017Date of Patent: June 29, 2021Assignees: ONO PHARMACEUTICAL CO., LTD., VANDERBILT UNIVERSITYInventors: Craig W Lindsley, Joshua M. Wieting, Kevin M. McGowan, Jerod S. Denton, Kentaro Yashiro, Haruto Kurata, Yoko Sekioka, Takahiro Mori, Yuzo Iwaki
-
Patent number: 10676438Abstract: The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.Type: GrantFiled: August 9, 2018Date of Patent: June 9, 2020Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Kentaro Yashiro, Daisuke Wakamatsu, Tetsuji Saito
-
Publication number: 20200157050Abstract: The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.Type: ApplicationFiled: January 24, 2020Publication date: May 21, 2020Applicant: Ono Pharmaceutical Co., Ltd.Inventors: Kentaro YASHIRO, Daisuke WAKAMATSU, Tetsuji SAITO
-
Patent number: 10570093Abstract: The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.Type: GrantFiled: August 9, 2018Date of Patent: February 25, 2020Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Kentaro Yashiro, Daisuke Wakamatsu, Tetsuji Saito
-
Patent number: 10519105Abstract: An object of the present invention is to provide a novel compound having a strong opening action with respect to KCNQ2-5 channels. A compound represented by the general formula (I) (wherein the definition of each group is as described in the specification) is provided. The compound represented by the general formula (I) has a strong opening action with respect to KCNQ2-5 channels, and therefore is useful as a prophylactic and/or therapeutic agent for a KCNQ2-5 channel-related disease (for example, dysuria, overactive bladder, or the like).Type: GrantFiled: April 21, 2017Date of Patent: December 31, 2019Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Kentaro Yashiro, Masashi Kato, Tetsuji Saito, Takuya Okada, Daisuke Wakamatsu, Adam James Davenport, Christopher Charles Stimson
-
Publication number: 20190322662Abstract: Disclosed is a compound of formula (I): wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and methods of using the compounds, compositions and kits for treatment of disorders associated with TREK-1, TREK-2 or both TREK-1 and TREK-2 dysfunction in a mammal.Type: ApplicationFiled: December 14, 2017Publication date: October 24, 2019Applicants: ONO PHARMACEUTICAL CO., LTD., Vanderbilt UniversityInventors: Craig W LINDSLEY, Joshua M. WIETING, Kevin M. MCGOWAN, Jerod S. DENTON, Kentaro YASHIRO, Haruto KURATA, Yoko SEKIOKA, Takahiro MORI, Yuzo IWAKI
-
Publication number: 20190135755Abstract: Crystal polymorphism may exist in a crystalline compound. In the case where crystal polymorphism exists, depending on the crystal form, solubility, dissolution rate, stability against heat, light, humidity, etc. or the like is different. Accordingly, in the production of a pharmaceutical product, it is a very important task to select a crystal form of a drug substance most suitable for a disease indication and a dosage form. The present invention relates to novel crystal forms (A crystal, W crystal, and a hydrate crystal (H crystal)) of a compound I having a strong opening action with respect to KCNQ2-5 channels.Type: ApplicationFiled: April 21, 2017Publication date: May 9, 2019Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Kentaro YASHIRO, Hideomi KIJIMA, Daisuke WAKAMATSU, Tetsuji SAITO
-
Publication number: 20190127320Abstract: An object of the present invention is to provide a novel compound having a strong opening action with respect to KCNQ2-5 channels. A compound represented by the general formula (1) (wherein the definition of each group is as described in the specification) is provided. The compound represented by the general formula (1) has a strong opening action with respect to KCNQ2-5 channels, and therefore is useful as a prophylactic and/or therapeutic agent for a KCNQ2-5 channel-related disease (for example, dysuria, overactive bladder, or the like).Type: ApplicationFiled: April 21, 2017Publication date: May 2, 2019Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Kentaro YASHIRO, Masashi KATO, Tetsuji SAITO, Takuya OKADA, Daisuke WAKAMATSU, Adam James DAVENPORT, Christopher Charles STIMSON
-
Patent number: 10196358Abstract: The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.Type: GrantFiled: August 8, 2017Date of Patent: February 5, 2019Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Kentaro Yashiro, Daisuke Wakamatsu, Tetsuji Saito
-
Publication number: 20180346422Abstract: The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.Type: ApplicationFiled: August 9, 2018Publication date: December 6, 2018Applicant: Ono Pharmaceutical Co., Ltd.Inventors: Kentaro Yashiro, Daisuke WAKAMATSU, Tetsuji SAITO
-
Publication number: 20170334855Abstract: The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.Type: ApplicationFiled: August 8, 2017Publication date: November 23, 2017Applicant: Ono Pharmaceutical Co., Ltd.Inventors: Kentaro Yashiro, Daisuke Wakamatsu, Tetsuji Saito
-
Patent number: 9809544Abstract: The present invention relates to a compound, 1-[(5-chloro-2-pyridinyl)methyl]-3-{2,6-dichloro-4-[(2S)-1,1,1-trifluoro-2-hydroxy-2-propanyl]phenyl}urea, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: October 23, 2015Date of Patent: November 7, 2017Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Kentaro Yashiro, Daisuke Wakamatsu, Tetsuji Saito
-
Publication number: 20170217888Abstract: The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.Type: ApplicationFiled: October 23, 2015Publication date: August 3, 2017Applicant: Ono Pharmaceutical Co., LtdInventors: Kentaro YASHIRO, Daisuke WAKAMATSU, Tetsuji SAITO